DOI: https://doi.org/10.22141/2224-0721.15.2.2019.166106

The place of the third generation sulfonylurea glimepiride in modern therapy of type 2 diabetes mellitus

L.V. Zhuravlyova, M.V. Filonenko

Abstract


The article considers the pharmacological and clinical aspects of the use of glimepiride, a third generation sulfonylurea, in modern therapy of type 2 diabetes mellitus. The drug is characterized by proven efficacy and safety, economical affordability, a number of favorable non-pancreatic effects, including cardioprotective properties. Everything mentioned above allows us to recommend it confidently for the treatment of type 2 diabetes mellitus.

Keywords


type 2 diabetes mellitus; sulfonylureas derivatives; glimepiride

References


Davies MJ, D’Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018 Dec;41(12):2669-2701. doi: 10.2337/dci18-0033.

Dovidnyk osnovnyh pokaznykiv dijal'nosti endokrynologichnoi' sluzhby Ukrai'ny za 2016 rik [A reference book of basic performance of endocrinology care of Ukraine indicators 2016]. Кyiv; 2017. 40 p. (in Ukrainian).

Singh GM, Danaei G, Farzadfar F, et al. The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. PLoS One. 2013 Jul 30;8(7):e65174. doi: 10.1371/journal.pone.0065174.

Abrahamson MJ. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? Yes, they continue to serve us well! Diabetes Care. 2015 Jan;38(1):166-9. doi: 10.2337/dc14-1945.

Barna OM, Pogrebniak OO. Effective and safe glycemic control when using gliclazide and glimepiride in the treatment of type 2 diabetes. Liky Ukrayiny. 2018;(2):21-28. (in Ukrainian).

Ruyatkina LA, Sorokin MY. Modern antihyperglycemic therapy: safety and efficacy of glimepiride. Diabetes mellitus. 2012;(2):89-97. (in Russian).

Smirnova OM, Kononenko IV. Amaryl ® (glimepiride) – representative of the third generation of sulphonylurea derivatives in treatment of type 2 diabetes mellitus. RMJ. 2011;19(27):1707-1713. (in Russian).

Basit A, Riaz M, Fawwad A. Glimepiride: evidence-based facts, trends, and observations (GIFTS). Vasc Health Risk Manag. 2012;8:463-72. doi: 10.2147/HIV.S33194.

World Health Organization. Global report on diabetes. 2016. Available from: https://www.who.int/diabetes/global-report/en/.

Lim PC, Chong CP. What’s next after metformin? Focus on sulphonylurea: Add-on or combination therapy. Pharm Pract (Granada). 2015 Apr-Jun;13(3):606. doi: 10.18549/PharmPract.2015.03.606.

Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: A meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013 Oct;15(10):938-53. doi: 10.1111/dom.12116.

Nakamura I, Oyama J, Komoda H, et al. Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: A preliminary report. Cardiovasc Diabetol. 2014 Jan 14;13:15. doi: 10.1186/1475-2840-13-15.

Schrijnders D, Wever R, Kleefstra N, et al. Addition of sulphonylurea to metformin does not relevantly change body weight: A prospective observational cohort study (ZODIAC-39). Diabetes Obes Metab. 2016 Oct;18(10):973-9. doi: 10.1111/dom.12700. 

Sola D, Rossi L, Schianca GP, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015 Aug 12;11(4):840-8. doi: 10.5114/aoms.2015.53304.

Kumar S, Pathak AK, Saikia D, Kumar A. Efficacy, Safety and Treatment Satisfaction of Glimepiride vs Sitagliptin in Combination with Metformin in Type 2 Diabetes Mellitus. J Clin Diagn Res. 2015 Dec;9(12):FC07-10. doi: 10.7860/JCDR/2015/17027.6888.

Varvaki Rados D, Catani Pinto L, Reck Remonti L, Bauermann Leitão C, Gross JL. The association between sulfonylurea use and all-cause and cardiovascular mortality: A meta-analysis with trial sequential analysis of randomized clinical trials. PLoS Med. 2016 Apr 12;13(4):e1001992. doi: 10.1371/journal.pmed.1001992.

Zhang Y, McCoy RG, Mason JE, Smith SA, Shah ND, Denton BT. Second-line agents for glycemic control for type 2 diabetes: Are newer agents better? Diabetes Care. 2014;37(5):1338-45. doi: 10.2337/dc13-1901.






Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2019

 

   Seo анализ сайта